Navigation Links
ImmunoVaccine Technologies Inc. Nears Phase I Clinical Trials with Completion of Scientific Advisory Board

HALIFAX, Sept. 27 /PRNewswire/ - ImmunoVaccine Technologies Inc. (IVT) finalizes an important step in its progress with the last appointment to its scientific advisory board (SAB), international oncology expert, Dr. Neil Berinstein.

Dr. Berinstein is the Global Head of the Cancer Vaccine Program at sanofi pasteur, and a professor at the University of Toronto's Department of Medicine. He has a long track record in fundamental research and has a significant publication record in the area of normal and malignant B cell biology, including articles, abstracts and book chapters on immunotherapeutic approaches for cancer including cancer vaccines. He was recently appointed vice-president of the Sabin Institute Cancer vaccine consortium. Dr. Berinstein received an MD from the University of Manitoba, and completed training programs at the University of Toronto in Internal Medicine and Medical Oncology. Following this, he spent four years as a post-doctoral fellow in Dr. Ron Levy's Lab at Stanford University working in the area of immunotherapy for cancer.

"IVT has very promising science," remarked Dr. Berinstein. "Their work is particularly interesting to me, and my commitment to new immunotherapeutic approaches for patients with cancer. "

ImmunoVaccine Technologies Inc. has been actively recruiting members to its SAB in preparation for its Phase I clinical trials, and sees this final appointment as a major stepping stone to that goal.

"This final appointment is one of the last steps before our Phase I clinical trials," said Dr. Martin Kast, chair of the scientific advisory board. "Dr. Berinstein's experience and insight are reflective of the quality of professionals that our exciting projects have attracted," continued Kast.

"Dr. Berinstein is a valuable addition to the team, and represents a pivotal point in our ongoing plan to introduce our patented vaccine platform," commented Dr. Randal Chase, president and CEO of IVT.

ImmunoVaccine Technologies Inc. (IVT) is a vaccine enhancement company focused on the commercialization of its patented VacciMax(R) platform. VacciMax(R) is a novel technology that can aid the development of new vaccines in human health applications with potential for both therapeutic cancer applications and preventative infectious disease vaccines. The opportunities for market applications and medical benefits are broad, and are currently being applied to cervical cancer, with potential for melanoma, breast, prostate and colon cancer treatments, as well as prevention therapies for influenza and other infectious diseases.

SOURCE ImmunoVaccine Technologies Inc
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Barriers will not stop convergence of medical technologies
2. Merge Technologies net loss doubles to $10.1M
3. Making deals with evolving technologies in mind
4. Third Wave Technologies to raise $14.9M through private debt
5. Meier joins Broadlook Technologies as COO
6. Platypus Technologies secures $450K SBIR grant
7. Napier joins board of Third Wave Technologies
8. aOva Technologies raises $3 million
9. Consumer, business technologies face same challenges
10. Promega to get early access to WARF technologies under new agreement
11. Linda Weber to run Fiservs Interactive Technologies unit
Post Your Comments:
(Date:11/26/2015)... MUMBAI , November 26, 2015 ... --> Accutest Research ... accredited Contract Research Organization (CRO), has ... Chase Cancer Center - Temple Health ... ,     (Photo: ) ...
(Date:11/25/2015)... Studies reveal the differences in species of bacteria ... for more effective treatment for one of the most commonly ... --> --> Gum disease is one ... relatively little was understood about the bacteria associated with it ... researchers from the WALTHAM Centre for Pet Nutrition together with ...
(Date:11/25/2015)... 2015 Orexigen® Therapeutics, Inc. (Nasdaq: OREX ... fireside chat discussion at the Piper Jaffray 27th Annual ... The discussion is scheduled for Wednesday, December 2, at ... A replay will be available for 14 days after ... Julie NormartVP, Corporate Communications and Business Development , BrewLife(858) ...
(Date:11/24/2015)... , Nov. 24, 2015 Cepheid (NASDAQ: ... speaking at the following conference, and invited investors to ... NY      Tuesday, December 1, 2015 at 11.00 ... NY      Tuesday, December 1, 2015 at 11.00 ... Conference, New York, NY      Tuesday, ...
Breaking Biology Technology:
(Date:11/10/2015)... , Nov. 10, 2015  In this ... the basis of product, type, application, disease ... in this report are consumables, services, software. ... are safety biomarkers, efficacy biomarkers, and validation ... report are diagnostics development, drug discovery and ...
(Date:11/2/2015)...  SRI International has been awarded a contract of ... to the National Cancer Institute (NCI) PREVENT Cancer Program ... modern testing and support facilities, and analytical instrumentation to ... studies to evaluate potential cancer prevention drugs. ... Drug Development Program is an NCI-supported pipeline to bring ...
(Date:10/29/2015)... BOSTON , Oct. 29, 2015  Connected health ... phenomena driving the explosion of technology-enabled health and wellness, ... his new book, The Internet of Healthy ... apps, sensors or smartphones even existed, Dr. Kvedar, vice ... model of health care delivery, moving care from the ...
Breaking Biology News(10 mins):